Infection with Chlamydia pneumoniae and Risk of Multiple Sclerosis

Background. Chlamydia pneumoniae (Cpn) has been proposed as a possible etiologic agent for multiple sclerosis (MS), but results of previous studies are conflicting. Methods. Using a nested case-control design, we examined the association between Cpn infection and MS in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS II) cohorts. Among 32,826 women in the NHS and 29,722 women in the NHS II with blood samples, 141 incident cases of definite or probable MS were documented. Each case was matched to two healthy controls on year of birth and NHS cohort. Serum samples were tested for the presence of Cpn-specific immunoglobin G antibodies using microimmunofluorescence. Results. Cpn immunoglobin G seropositivity was positively associated with risk of MS (odds ratio [OR] = 1.7; 95% confidence interval [CI] = 1.1–2.7). This association did not change after adjusting for age at blood collection, ancestry, latitude of residence at birth, and smoking (OR = 1.9; CI = 1.1–3.1). Seropositivity for Cpn was only moderately associated with risk of relapsing-remitting MS (OR = 1.7; CI = 0.9–3.2), but it was strongly associated with risk of progressive MS (OR = 7.3; CI = 1.4–37.2). Geometric mean titers of Cpn-specific immunoglobin G antibody were similar in women with relapsing-remitting MS as compared with matched controls (44 vs 39), but they were elevated in women with progressive MS (99 vs 40). Conclusions. These results support a positive association between Cpn infection and progressive MS.

[1]  S. Dimauro,et al.  Autosomal dominant limb-girdle muscular dystrophy , 2001, Neurology.

[2]  S.‐P. Wang.  Serology for Chlamydia pneumoniae (TWAR) , 1999 .

[3]  G. Byrne,et al.  Copyright © 1997, American Society for Microbiology Reactivation of Chlamydial Genital Tract Infection in Mice , 1997 .

[4]  A. E. Campbell,et al.  Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. , 1998, The Journal of infectious diseases.

[5]  C. Stratton,et al.  Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis , 1999, Annals of neurology.

[6]  C. Gaydos.  Chlamydia pneumoniae and its proposed link to multiple sclerosis: To be or not to be? , 2001, Neurology.

[7]  R. Peeling.  Chlamydia pneumoniae Infections: Applications of Laboratory Methods , 1999 .

[8]  C. Kuo,et al.  Reactivation of Chlamydia trachomatis lung infection in mice by cortisone , 1983, Infection and immunity.

[9]  Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS , 2000 .

[10]  C. Stratton,et al.  Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS , 1998, Neurology.

[11]  C. Stratton,et al.  CME CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens , 2005 .

[12]  D. Hafler.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. , 1999, The Journal of clinical investigation.

[13]  J. Hedrick,et al.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. , 1995, The Pediatric infectious disease journal.

[14]  B. Weinshenker,et al.  Natural history of multiple sclerosis. , 2005, Neurologic clinics.

[15]  M. Hammerschlag,et al.  Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. , 1998, The Journal of infectious diseases.

[16]  M. Leinonen,et al.  Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment , 1996, Infection and immunity.

[17]  R. Malinverni,et al.  Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. , 1995, The Journal of infectious diseases.

[18]  R. Peeling,et al.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Peeling,et al.  Association of Chlamydia trachomatis heat-shock protein 60 antibody and HLA class II DQ alleles. , 1999, The Journal of infectious diseases.

[20]  T. Derfuss,et al.  Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. , 2001, Brain : a journal of neurology.

[21]  A. Cross,et al.  Association of Chlamydia pneumoniae and multiple sclerosis: Stage two? , 2001, Neurology.

[22]  A. Grau,et al.  Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis , 2000, Annals of neurology.

[23]  F. Hanefeld,et al.  Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis , 2001, Annals of neurology.

[24]  G. Rosati,et al.  Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls , 2001, Multiple sclerosis.

[25]  G. McDonnell,et al.  Major histocompatibility complex class II alleles and the course and outcome of MS. , 1999, Neurology.

[26]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[27]  S. Menzo,et al.  Lack of Chlamydia infection of the central nervous system in multiple sclerosis , 2000, Annals of neurology.

[28]  D Spiegelman,et al.  Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. , 2001, JAMA.

[29]  M. Hernán,et al.  Geographic variation of MS incidence in two prospective studies of US women , 1999, Neurology.

[30]  B. Vastag.  Not so fast: research on infectious links to MS questioned. , 2001, JAMA.

[31]  G A Colditz,et al.  Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[32]  D. Schaid,et al.  Major histocompatibility complex class II alleles and the course and outcome of MS , 1998, Neurology.

[33]  P. Saikku,et al.  A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR , 1990, The Journal of infectious diseases.

[34]  C. Polman,et al.  Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients? , 2000, Annals of neurology.

[35]  A. Berghold,et al.  Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker , 2001, Multiple sclerosis.

[36]  R. Peeling,et al.  Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. , 2000, The Journal of infectious diseases.

[37]  M. Hammerschlag,et al.  Is Chlamydia pneumoniae Present in Brain Lesions of Patients with Multiple Sclerosis? , 2000, Journal of Clinical Microbiology.